BridgeMD
New treatment option for Renal Function Disorder
Official title Impact of Intravitreal Faricimab on Renal Function in Diabetic Patients
ClinicalTrials.gov ID: NCT06929507
What this study is testing
What is Intravitreal injection of Faricimab or Aflibercept 2 mg?
Intravitreal injection of Faricimab or Aflibercept 2 mg is an investigational medicine, given as an injectable medicine, being studied as a potential treatment for renal function disorder.
Also referred to as Vabysmo, Eylea.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study aims to investigate the impact of intravitreal injection of anti-vascular endothelial growth factor (anti VEGF) Faricimab on renal function of diabetic patients. Faricimab is a new anti-VEGF drug which inhibits both VEGF-A and Ang-2 and it is used for the treatment of diabetic macular edema and neovascular age related macular degeneration.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Adults
You may be able to join if
- Patients with diabetes
- Patients with DME or nAMD or macular edema secondary to retinal vein occlusion
- Patients already receiving nephroprotective drugs
You likely can't join if
- Patients with end stage renal disease
- Pregnancy
- Patients with other retinal disorders
- Previous renal transplantation Patients under hemodialysis
The study team makes the final eligibility decision.
Where it's taking place
- Alexandroupoli, Evros, Greece
- Alexandroupoli, Greece
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, not specified. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Alexandroupoli, Evros, Greece; Alexandroupoli, Greece. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.